PL3383376T3 - Sposoby hamowania przemiany choliny w trimetyloaminę (tma) - Google Patents

Sposoby hamowania przemiany choliny w trimetyloaminę (tma)

Info

Publication number
PL3383376T3
PL3383376T3 PL16819754T PL16819754T PL3383376T3 PL 3383376 T3 PL3383376 T3 PL 3383376T3 PL 16819754 T PL16819754 T PL 16819754T PL 16819754 T PL16819754 T PL 16819754T PL 3383376 T3 PL3383376 T3 PL 3383376T3
Authority
PL
Poland
Prior art keywords
carnitine
tma
trimethylamine
methods
inhibiting conversion
Prior art date
Application number
PL16819754T
Other languages
English (en)
Inventor
Stanley Leon Hazen
Jose Carlos Garcia-Garcia
George Franklin Gerberick
John August Wos
David Thomas Stanton
Thomas Alfred Inglin
Michael Reilly
Angela Jane Deutsch
Jodie Michelle Reed
David Blair Cody
Original Assignee
The Procter & Gamble Company
The Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Company, The Cleveland Clinic Foundation filed Critical The Procter & Gamble Company
Publication of PL3383376T3 publication Critical patent/PL3383376T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/36—Compounds containing oxirane rings with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16819754T 2015-12-01 2016-12-01 Sposoby hamowania przemiany choliny w trimetyloaminę (tma) PL3383376T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562261645P 2015-12-01 2015-12-01
US201562261662P 2015-12-01 2015-12-01
US201662356422P 2016-06-29 2016-06-29
EP16819754.9A EP3383376B1 (en) 2015-12-01 2016-12-01 Methods for inhibiting conversion of carnitine to trimethylamine (tma)
PCT/US2016/064341 WO2017095995A1 (en) 2015-12-01 2016-12-01 Methods for inhibiting conversion of carnitine to trimethylamine (tma)

Publications (1)

Publication Number Publication Date
PL3383376T3 true PL3383376T3 (pl) 2021-10-04

Family

ID=57680518

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16819754T PL3383376T3 (pl) 2015-12-01 2016-12-01 Sposoby hamowania przemiany choliny w trimetyloaminę (tma)

Country Status (10)

Country Link
US (3) US10213407B2 (pl)
EP (3) EP3383377B1 (pl)
CN (3) CN108472267B (pl)
AU (4) AU2016362298B2 (pl)
BR (3) BR112018010873A2 (pl)
CA (3) CA3007081C (pl)
MX (3) MX383038B (pl)
PL (1) PL3383376T3 (pl)
RU (3) RU2018116864A (pl)
WO (3) WO2017095995A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095995A1 (en) 2015-12-01 2017-06-08 The Procter & Gamble Company Methods for inhibiting conversion of carnitine to trimethylamine (tma)
US11298334B2 (en) * 2016-04-22 2022-04-12 Jc (Wuxi) Company, Inc. Use of isothiocyanate compounds
AU2017291211B2 (en) 2016-06-29 2020-06-25 Cleveland Clinic Innovation Methods for inhibiting conversion of choline to trimethylamine (TMA)
US11419882B2 (en) * 2017-06-08 2022-08-23 Allergyintellect, Inc Vitamin D compounds and methods of using the same
WO2018236899A1 (en) * 2017-06-19 2018-12-27 The Cleveland Clinic Foundation Treating disease and promoting weight loss by inhibiting the tma/fmo3/tmao pathway
KR20200052298A (ko) * 2017-08-14 2020-05-14 소마젠 인크 트리메틸아민 및/또는 트리메틸아민 n-옥사이드 관련 표적화된 약물
WO2019070676A1 (en) 2017-10-02 2019-04-11 The Procter & Gamble Company METHODS OF INHIBITING CONVERSION FROM CHOLINE TO TRIMETHYLAMINE (TMA)
WO2019070678A1 (en) * 2017-10-02 2019-04-11 The Procter & Gamble Company METHODS OF INHIBITING CONVERSION FROM CHOLINE TO TRIMETHYLAMINE (TMA)
CA3076232C (en) * 2017-10-02 2023-05-16 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (tma)
CN108976485B (zh) * 2018-01-22 2020-11-03 内蒙古大学 一种凝胶多糖与稀土复合的柔性发光薄膜及其制备方法
US12576055B2 (en) 2018-02-01 2026-03-17 The Cleveland Clinic Foundation Disease detection and treatment based on trimethyl-lysine levels
AU2019377820B2 (en) * 2018-11-06 2022-08-11 The Cleveland Clinic Foundation Methods for inhibiting conversion of choline to trimethylamine (TMA)
CA3117566C (en) 2018-11-06 2024-04-09 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (tma)
US12162902B2 (en) * 2018-12-06 2024-12-10 Sail Biomedicines Decarboxylase inhibitors for treating Parkinson's disease

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242863A (en) * 1968-05-10 1971-08-18 Pharmacia As 2,3-DIHYDRO-5H-THIAZOLO[2,3-b]QUINAZOLINES AND PROCESSES FOR THE PREPARATION THEREOF
US4335141A (en) 1979-12-26 1982-06-15 Merck & Co., Inc. 2-Substituted-aminopropene-and propanenitrile antimicrobial and anti-inflammatory agents
US4874788A (en) 1985-10-01 1989-10-17 Ethyl Corporation Quaternary ammonium compounds
US5547677A (en) * 1994-05-20 1996-08-20 Novavax, Inc. Antimicrobial oil-in-water emulsions
AU750851B2 (en) 1998-08-21 2002-08-01 Ciba Specialty Chemicals Holding Inc. Thermal- and photoinitiated radical polymerization in the presence of an addition fragmentation agent
WO2002016366A1 (en) 2000-08-23 2002-02-28 Itoi Textile Co., Ltd Copper or iron chlorophyllin sodium, pulp, aqueous pigment solution, paper yarn and process for producing the same
JP4099012B2 (ja) 2002-07-12 2008-06-11 富士フイルム株式会社 画像形成材料
JP4798973B2 (ja) 2004-08-04 2011-10-19 丸善製薬株式会社 抗菌用組成物
US20070199890A1 (en) 2006-02-27 2007-08-30 Agion Technologies, Inc. Antimicrobial activated carbon and use thereof
US8859798B2 (en) 2006-07-06 2014-10-14 Rutgers, The State University Of New Jersey Isothiocyanate compounds, pharmaceutical compositions, and uses thereof
EP2059807B1 (en) * 2006-08-17 2013-02-20 The UAB Research Foundation Diagnosing pneumococcal pneumonia
WO2009073839A1 (en) * 2007-12-05 2009-06-11 The Cleveland Clinic Foundation Trimethylamine compounds as risk predictors of cardiovascular disease
WO2010084661A1 (ja) * 2009-01-23 2010-07-29 金印株式会社 イソチオシアネート類含有組成物、食品、食品素材、医薬品、化粧品および日用品雑貨類
US10241093B2 (en) 2009-05-28 2019-03-26 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
CA2790371C (en) * 2009-05-28 2020-09-01 The Cleveland Clinic Foundation Trimethylamine-containing compounds for diagnosis and prediction of disease
WO2010140902A1 (en) 2009-06-02 2010-12-09 Mark Hampton Inhibitors of macrophage migration inhibitory factor
GB0922505D0 (en) * 2009-12-23 2010-02-10 Plant Bioscience Ltd Use
US20120225020A1 (en) 2011-02-24 2012-09-06 Chekmenev Eduard Y Unsaturated choline analogs and chemical synthesis thereof
AU2013274406B2 (en) * 2012-06-11 2017-02-02 The Cleveland Clinic Foundation Treatment and prevention of cardiovascular disease and thrombosis
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
EP3200792A4 (en) 2014-10-03 2018-05-09 The Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad
WO2017095995A1 (en) 2015-12-01 2017-06-08 The Procter & Gamble Company Methods for inhibiting conversion of carnitine to trimethylamine (tma)
AU2017291211B2 (en) 2016-06-29 2020-06-25 Cleveland Clinic Innovation Methods for inhibiting conversion of choline to trimethylamine (TMA)

Also Published As

Publication number Publication date
CN108472267A (zh) 2018-08-31
EP3383377A1 (en) 2018-10-10
RU2018116864A (ru) 2020-01-09
AU2016365316B2 (en) 2019-11-07
US20170152222A1 (en) 2017-06-01
CN108601753A (zh) 2018-09-28
WO2017095995A1 (en) 2017-06-08
CA3005760C (en) 2019-10-08
RU2018120189A3 (pl) 2020-01-10
BR112018011210A2 (pt) 2018-11-21
AU2016362298B2 (en) 2019-07-25
CN108472267B (zh) 2021-12-24
US10780072B2 (en) 2020-09-22
CA3007061A1 (en) 2017-06-08
RU2018120183A3 (pl) 2020-01-10
EP3383378B1 (en) 2024-04-17
US10786479B2 (en) 2020-09-29
CA3007061C (en) 2021-03-16
AU2019280094A1 (en) 2020-01-16
MX383038B (es) 2025-03-13
RU2018120189A (ru) 2020-01-10
US20170151208A1 (en) 2017-06-01
CA3007081C (en) 2022-03-29
AU2016365316A1 (en) 2018-06-21
CA3005760A1 (en) 2017-06-08
AU2016362298A1 (en) 2018-05-31
AU2016365314A1 (en) 2018-06-21
CN108601754A (zh) 2018-09-28
US10213407B2 (en) 2019-02-26
MX378437B (es) 2025-03-11
EP3383377B1 (en) 2024-04-17
BR112018011216A2 (pt) 2018-11-21
MX380818B (es) 2025-03-12
AU2019280094B2 (en) 2021-09-16
RU2018116864A3 (pl) 2020-01-09
US20170151250A1 (en) 2017-06-01
WO2017095975A1 (en) 2017-06-08
EP3383376B1 (en) 2021-05-12
CA3007081A1 (en) 2017-06-08
BR112018010873A2 (pt) 2019-04-30
EP3383376A1 (en) 2018-10-10
WO2017095993A1 (en) 2017-06-08
RU2018120183A (ru) 2020-01-10
EP3383378A1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
PL3383376T3 (pl) Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
IL257219B (en) Prodrugs of glutamine analogs
IL256499A (en) Antibodies to CD40
IL253503A0 (en) Allele-specific modulators of p23h rhodopsin
PL3478276T3 (pl) Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
GB201608428D0 (en) Improved alignment of flanged components
GB201507524D0 (en) Improvements to molybdenum containing coatings
GB201515000D0 (en) Reactor
PL3151351T3 (pl) Udoskonalenia odcinków koryt kablowych
SG11201709722TA (en) Reactor
ZA201706282B (en) Solid forms of menaquinols
SG11201802987UA (en) Formulation of l-ornithine phenylacetate
SG11201709564VA (en) Reactor
GB201512678D0 (en) Methods of chemical synthesis
PL3522927T3 (pl) Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
PT3393517T (pt) Ácido acetilsalicílico para utilização no tratamento de influenza moderada a grave
PL3522878T3 (pl) Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
GB2538045B (en) Improvements to letter-plates
GB2528112B (en) Improvements relating to inhibition of corrosion
IL250846A0 (en) Synthesis of cyclocreatin and its analogs
PL3522876T3 (pl) Sposoby hamowania przemiany choliny w trimetyloaminę (tma)
GB201401237D0 (en) Improvements to satellite positioning methods
ZA201802544B (en) Methods for total synthesis of resolvin e1
GB2550166B (en) Improvements to letter-plates
GB201514076D0 (en) Reactor